![]() #Zocor heart pro professionalIt's important to talk to your healthcare professional about your 10-year or lifetime risk. Some people who don't fall into these categories may also benefit from statin therapy. Adults 40-75 years with LDL-C level of 70-189 mg/dL and a 20% or greater 10-year risk of developing cardiovascular disease from atherosclerosis.Adults 40-75 years with LDL-C level of 70-189 mg/dL and a 5% to 19.9% 10-year risk of developing cardiovascular disease from atherosclerosis and risk-enhancing factors.Those with LDL-C level of greater than 190 mg/dL.Adults with a history of cardiovascular disease, including stroke, caused by atherosclerosis.Guidelines recommend that people in any of these groups talk to their doctor about the risks and benefits of statin therapy: Statins are recommended for most patients and have been directly associated with a reduction in the risk of heart attack or stroke. Statins continue to provide the most effective lipid-lowering treatment in most cases. Various medications can lower blood cholesterol levels. The potential benefit to your health is worth making these medications part of your normal routine. If medication is required, be sure to take it as prescribed. Work with your doctor to develop a treatment plan that’s right for you. For others with high cholesterol, medication may also be needed. National Hypertension Control Initiativeįor some people, lifestyle changes, such as a healthier diet and more exercise, may prevent or treat unhealthy cholesterol levels.Pets and Your Health / Healthy Bond for Life. ![]() #Zocor heart pro fullThe MHRA said in a statement that the full and correct facts had been put in front of the Committee on the Safety of Medicines, the experts which made the final decision. The Royal College of Paediatrics and Child Health expressed concern about potential long-term side-effects and worried that neither GPs nor pharmacists would know what drugs a patient was on. ![]() The National Patient Safety Agency's letter said: "If there is no direct or indirect danger to health when simvastatin is used without medical supervision, the question begs why have other countries not reclassified the drug as safe to use OTC ?" Among responses now categorised as "not opposed but raised issues to be considered" are letters which appear entirely critical of the proposal. Yesterday the MHRA did a u-turn and apologised "for any confusion caused by this error".īut the final count is still in question, said Dr Iheanacho. In April, after the Bulletin scrutinised those responses to the consultation which had been made public and told the MHRA the figure of two-thirds could not be right, the agency issued a robust denial. "The MHRA displayed a mixture of arrogance and carelessness which is certainly not ideal in a body supposed to protect the public." "The MHRA has stated that it has made an 'administrative error' but there must be concerns that it dressed up the consultation responses to support its own decision to make simvastatin available over the counter," he said. "Their job is to protect people but this latest episode totally undermines faith in their decision-making process."ĭr Iheanacho said that even now, after a highly critical report earlier this year by the Commons health select committee, which objected to a lack of openness by the MHRA and its closeness to the pharmaceutical industry, too many decisions were being made behind closed doors. ![]() "This has got to be the killer argument for a massive overhaul of the MHRA," said Dr Ike Iheanacho. The MHRA said there had been "an administrative error".īut the editor of the Bulletin, published by Which?, said yesterday that the episode cast doubt on the entire decision-making process at the MHRA. Only one third of those who responded agreed unequivocally with the change of status of the drug, one third did not agree and the rest had reservations. Yesterday, however, after a battle with the consumer publication Drug and Therapeutics Bulletin, it conceded that the figures were wrong. The MHRA last year announced that two-thirds of those consulted were in favour of the drug being sold in pharmacies. But there was concern about side-effects of the drug, generically known as simvastatin, and also that some people who need stronger medication would buy it rather than see a doctor. The government was in favour, hoping it would reduce heart attacks and cut NHS bills since some people would buy the drug rather than get it on prescription. Allowing people to buy the drug without seeing a doctor was a world first. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |